搜尋
Spero Therapeutics Inc
SPRO添加自選
2.200USD
-0.020-0.90%
收盤 07/02, 13:00（美東）報價延遲15分鐘
127.38M總市值
7.92本益比TTM
關於 Spero Therapeutics Inc 公司
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Spero Therapeutics Inc簡介
公司代碼SPRO
公司名稱Spero Therapeutics Inc
上市日期Nov 02, 2017
CEORajavelu (Esther)
員工數量32
證券類型Ordinary Share
年結日Nov 02
公司地址675 Massachusetts Ave Ste 14
城市CAMBRIDGE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編02139-3309
電話18572421600
網址https://sperotherapeutics.com/
公司代碼SPRO
上市日期Nov 02, 2017
CEORajavelu (Esther)
Spero Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-1.80%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
335.13K
+55.82%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
229.84K
-10.98%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
71.45K
-27.99%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
55.00K
-36.36%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
55.00K
-36.36%
Ms. Kathleen Tregoning
Ms. Kathleen Tregoning
Independent Director
Independent Director
55.00K
-36.36%
Dr. Patrick Volkert Jozef Johannes Vink, M.D.
Dr. Patrick Volkert Jozef Johannes Vink, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. John C. Pottage, Jr., M.D.
Dr. John C. Pottage, Jr., M.D.
Independent Director
Independent Director
--
--
Mr. Scott T. Jackson
Mr. Scott T. Jackson
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-1.80%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
335.13K
+55.82%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
229.84K
-10.98%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
71.45K
-27.99%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
55.00K
-36.36%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
55.00K
-36.36%
常見問題
Spero Therapeutics Inc的前五大股東是誰？
Spero Therapeutics Inc的前五大股東如下：Dr. Ankit Mahadevia, M.D.
有多少機構持有Spero Therapeutics Inc(SPRO)的股份？
截至2026Q1，共有117家機構持有Spero Therapeutics Inc的股份，合計持有的股份價值約為11.81M，占公司總股份的20.40% 。與2025Q4相比，機構持股有所增加，增幅為-1291189.00。
哪個業務部門對Spero Therapeutics Inc的收入貢獻最大？
在2026Q1，Collaboration Revenue Related Party業務部門對Spero Therapeutics Inc的收入貢獻最大，創收47.03M，占總收入的70.41% 。